Question and Answer Solicitation amendment W81K00-26-Q-A048 00002 (REVISEDV2) 31 DEC 25.pdf

Solicitation W81K0026QA048 Question and Answer

Question 1: In review of the actual documents it sounds like this is a formal RFP however the notice type indicates Sources Sought. Could you please just clarify?

Answer 1: Yes, this is a solicitation RFQ. That is noted in the body of the posting. The solicitation # changed from the sources sought #. The solicitation is “W81K0026QA048”.

Question 2: We do not see 52-212-1 ADDENDUM or 52-212-2 ADDENDUM posted.

Answer: 2: The Addendum to 52.212-1 and Addendum to 52.212-2 are in the body of the solicitation.

Question3: The Solicitation we pulled has DRAFT printed across Page 1 STANDARD FORM 1449 (REV.

11/2021).

Answer 3: Solicitation amendment 0001 was issued to remove DRAFT.

Question 4: can 9.4 be clarified, specifically “if the analyzer cannot be repaired within eight (8) hours of the initial notification, the Contractor shall, where requested, arrange the pickup and delivery of critical specimens to a College of American Pathologists accredited clinical laboratory using FDA approved assays…”

Answer 4: Section 9.4 has been updated.

Quention 5: Respectfully requesting clarification on the test labeled “CKI” and if that is referring to “CK”:

Creatine Kinase.

Answer 5: Yes, the CKI is Creatine Kinase.

Question 6: Please confirm the standalone system will accept a NEMA L6-30R receptacle for requirement

7.11 in the Statement of Work.

Answer 6: Standalone system will accept a NEMA L6-30R.

Question 7: Can you please highlight the page # and paragraph where we can find 52.212-1 and 52.212-

2?

Answer 7: The Addendum to 52.212-1 and Addendum to 52.212-2 are in the body of the solicitation starting on page 121.

Question 8: Please consider an extension of the due date so vendors have at least 10 business days to adjust responses after receiving answers to all vendor questions.

Answer 8: Solicitation due date will remain as is, 16 January 2026 at 2:00 p.m. Central Standard Time as noted in Block 8 of the solicitation.

Question 9: CLINs 0001AX/1001AX/2001AX/3001AX/4001AX appear to have “Uric Acid” added to the description, but the test count only reflects the Blood Urea Nitrogen volume of 6,500 found in the

Volume chart on page 103. Please clarify if CLIN 0001AX should only be “Blood Urea Nitrogen” and not

“Blood Urea Nitrogen Uric Acid (BUN)” as currently stated.

Answer 9: Yes, CLIN 001AX should be ONLY Blood Urea Nitrogen. Uric Acid is 0001BE. CLIN descriptions have been updated.

Question 10: Page 24 also lists this assay as “Blood Urea Nitrogen Uric Acid”. Please clarify if this assay should only be “Blood Urea Nitrogen” and not “Blood Urea Nitrogen Uric Acid” as currently stated.

Answer 10: Yes, CLINs stating “Blood Urea Nitrogen Uric Acid” should be ONLY Blood Urea Nitrogen.

CLINs have been updated.

Question 11: Please confirm if Magnesium should be included. If so, what is the annual volume? A CLIN would need to be added each year for this assay.

Answer 11: Magnesium is not included due to low test volumes ordered.

Question 12: Please confirm if Microalbumin (urine) should be included. If so, what is the annual volume? A CLIN would need to be added each year for this assay.

Answer 12: (urine) Microalbumin is not included due to low test volumes ordered.

Question 13: Please confirm if Total PSA (Prostate-Specific Antigen) should be included. If so, what is the annual volume? A CLIN would need to be added each year for this assay.

Answer 13: PSA (Prostate-Specific Antigen) is not included due to low test volumes ordered.

Question 14: Is the vendor to provide linearity material for the duration of the contract for all assays listed?

Answer 14: Yes, for all assays that do not have a three-point calibration. See PWS paragraph 9.5.

Question 15: To provide an accurate quote, please provide answers to each of these Quality Control questions.

a. Please provide the current quality control vendor.

Answer 15a: BioRad

b. Please provide exactly which quality control products are used today and their annual quantity used.

Answer 15b: Liquid Assayed Multiqual 20ea. (12 x 3 mL), Liquichek Immunoassay Plus

Control, Trilevel 20Ea. (12 x 5 mL), Liquichek Diabetes Control 15ea. (6 x 1 ml)

c. Please provide how many levels and which levels of quality control products are used for each assay today and should be used for this solicitation response.

Answer 15c: Liquid Assayed Multiqual Levels 1 and 3. Liquichek Immunoassay Plus Control

Levels 1, 2, 3. Liquichek Diabetes Control levels 1 and 2.

Question 16: Page 25, “Must fit into existing laboratory floorplan. Maximum length (with UPS) 110 inches, maximum depth (with monitor extended) 65 inches”

a. Please clarify if this requirement is for the actual instrument or if it also includes the total allowable space around the instrument, too, to include walkways and service access.

Answer 16a: This is for the actual instrument and does not include walkway and service access. A 65” analyzer depth will allow for an additional 70” of walkway and service access in our facility.

b. If this includes walkways and service access, please extend the depth to 100” as it is currently source limiting at 65”.

Answer 16b: See 16a.

Question 17: Page 59 – “Delivery Period From 01 Apr 2030 to 31 Mar 2031”

a. Should this Delivery Period actually start on 01 Apr 2026?

Answer 17: ATTTENTION: The delivery period for this requirement has changed.

Due to a glitch in our system, currently we are unable to update the delivery period.

The delivery period will be updated at the time of award.

Delivery period has changed as described below:

Base Year: 1 April 2026 to 31 March 2027 TO: 1 April 2026 to 30 September 2026 (Six Months)

OY1: 1 April 2027 to 31 March 2028 TO: 1 October 2026 to 30 September 2027 https://www.bio-rad.com/en-us/sku/360-liquichek-immunoassay-plus-control-trilevel?ID=360 https://www.bio-rad.com/en-us/sku/360-liquichek-immunoassay-plus-control-trilevel?ID=360 https://www.bio-rad.com/en-us/sku/360-liquichek-immunoassay-plus-control-trilevel?ID=360

OY2: 1 April 2028 to 31 March 2029 TO: 1 October 2027 to 30 September 2028

OY3: 1 April 2029 to 31 March 2030 TO: 1 October 2028 to 30 September 2029

OY4: 1 April 2030 to 31 March 2031 TO: 1 October 2029 to 30 September 2030

Question 18: Page 101, “6.7 The Contractor shall provide with its quotation a transitioning plan for the complete transition to including installation and training of personnel, transition of all testing materials, reagents and supplies, etc., performance of all comparisons and validations. This transition shall be completed no later than 60 days after date of award.”

a. Industry standard is to allow 90 days for this transition. Please revise to 90 days.

Answer 18: Revised from 60 to 90 days after date of award. See revised PWS.

Question 19: Page 102, “6.7 Up to 10 operator level training during installation”

a. Please confirm if these training positions are for key operators or if training is to be conducted for users onsite at the laboratory location.

Answer 19: Training is to be conducted for users onsite at the laboratory location.

Question 20: Page 104, “9.4 For repairable equipment supporting the Laboratory, the service engineer shall be on-site to provide unlimited service within twenty-four (24) hours of establishing telephonic contact. The equipment shall be repaired and operational within 48 hours after initial on-site response by the Contractor. If deemed necessary, after consultation with the government representative, if the analyzer cannot be repaired within eight (8) hours of the initial notification, the Contractor shall, where requested, arrange the pickup and delivery of critical specimens to a College of American

Pathologists accredited clinical laboratory using FDA approved assays, with priority testing service provided for ASAP specimens. The Contractor shall pay all costs associated with the provision of this alternative testing, including those for delivery of hardcopy patient results by express courier, directly to the laboratory, for as long as the analyzer remain inoperable.”

a. Please revise and/or remove the highlighted section as vendors are not permitted to ”pickup and deliver” specimen samples, per regulations and accrediting agencies.

Answer 20: PWS section 9.4 has been updated.

Question 21: Page 104, “10. If a relocation is necessary. The Contractor shall relocate / revalidate their instrument/s one time per laboratory relocation, including any location within the LAHC healthcare network. Any additional relocations /revalidations needed must be negotiated between the contracting officer and the contractor.”

a. Please specify the maximum distance of this potential relocation. It is to be within the same laboratory, same floor, same facility, or same geographic campus? Please provide distance details in order to provide the vendor the information needed to prepare the quote appropriately.

Answer 21: No relocation is anticipated during contract periods of performance. If relocation is required, it will likely be on same floor, with a maximum distance of the same geographic location on the government installation.